COMMUNIQUÉS West-GlobeNewswire

-
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
29/09/2025 -
Consortium consisting of Nordic Capital and Permira extends offer period until 14 October 2025 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic
29/09/2025 -
Spectral Medical Inc. Files Base Shelf Prospectus and Revised AIF
29/09/2025 -
Tria Federal Unveils Tria Forge, a Serverless AI Platform That Empowers Organizations to Build Secure, Codeless AI Tools
29/09/2025 -
Fagron increases share capital through exercise subscription rights
29/09/2025 -
MindRank Announces Positive 12-week Once-Daily (QD) Results for AI-Designed Oral GLP-1 Agonist MDR-001 in Adults with Obesity
29/09/2025 -
Reflect Scientific Secures Over $1 Million in Follow-On Orders for B-90 Blast Freezer
29/09/2025 -
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
29/09/2025 -
Apyx Medical to Host Virtual Key Opinion Leader Event to Discuss the Commercial Launch of The AYON Body Contouring System™ on October 14, 2025
29/09/2025 -
Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
29/09/2025 -
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
29/09/2025 -
electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
29/09/2025 -
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum
29/09/2025 -
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
29/09/2025 -
Neura Health Secures $11.4 Million Series A to Fuel National Expansion of Comprehensive, Tech-Enabled Neurology Care Model
29/09/2025 -
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
29/09/2025 -
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
29/09/2025 -
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
29/09/2025 -
Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer
29/09/2025
Pages